Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC
Published on 6 October 2026
Dr Luis Paz-Ares summarises the DELPHI-308 phase 1 trial of subcutaneous talquetamab for extensive-stage small cell lung cancer.
The study details safety, dosing, and preliminary efficacy, highlighting a 30% response rate and manageable side effects.
Dr Paz-Ares says that the findings suggest talquetamab's significant potential in treating this challenging cancer.
This information is intended for health care professionals only. The information is not intended for US health care professionals.